Held by 2 specialist biotech funds
Eventide's $1.8M initiation in Lumentum (optical and photonic components supplier) suggests conviction in secular tailwinds for biotech instrumentation, potentially driven by increased R&D spending on next-gen sequencing, lab automation, and diagnostic platforms that rely on LITE's core products. The timing aligns with anticipated biotech funding recovery and accelerating adoption of high-throughput genomic technologies across biopharma and clinical labs.